Abstract
Earlier studies from our laboratory have indicated insulin sensitizing action of chromium picolinate as the mechanism of its anti‐diabetic activity in experimental models of type I and type II diabetes. In the present investigation, we have evaluated the effects of chronic administration of chromium picolinate on the functional and histological alterations of streptozotocin (STZ)‐induced diabetes in rats. Type I diabetes was induced by intravenous injection of STZ (40 mg/kg) in adult rats, whereas, type II diabetes was induced by intraperitoneal injection of STZ (90 mg/kg) in 2‐day old rat pups which in adulthood develop abnormalities resembling type II diabetes. Chromium picolinate was administered at 8 μg/ml in drinking water for 6 weeks and was found to improve glucose tolerance and increase insulin sensitivity of STZ‐diabetic rats. This treatment decrease elevated serum creatinine and urea levels as well as elevated serum levels of hepatic enzymes of both groups of diabetic rats. Histopathological studies of kidney and liver show decrease in the intensity and incidence of vacuolations, cellular infiltration and hypertrophy of STZ and nSTZ (neonatal STZ) diabetic rats. Chronic treatment with chromium picolinate however, did not alter the normal function or morphology of control rats. Chronic chromium picolinate at the therapeutic doses that improved glucose tolerance, was observed to have no hepatotoxic or nephrotoxic potential. It was rather found to improve renal and hepatic function and to reduce abnormalities associated with STZ‐diabetes. Chromium picolinate could play an important role in the long term management of diabetes mellitus.
Keywords: chromium picolinate, streptozotocin, diabetes mellitus, renal function, hepatic function, histopathology
References
- 1. DeFronzo R.A., Lilly Lecture 1987: the triumvirate: ‐cell, muscle, liver: a collusion responsible for NIDDM, Diabetes, 37: 667–687, 1988. [DOI] [PubMed] [Google Scholar]
- 2. Bailey C.J., Potential new treatments for type 2 diabetes, TIPS, 21: 259–265, 2000. [DOI] [PubMed] [Google Scholar]
- 3. Mertz W., Chromium in human nutrition: a review, J. Nutr., 123: 626–633, 1993. [DOI] [PubMed] [Google Scholar]
- 4. Anderson R.A., Chromium, glucose tolerance, diabetes and lipid metabolism, J. Adv. Med., 8: 37–49, 1995. [Google Scholar]
- 5. Anderson R.A., Recent advances in the clinical and biochemical manifestation of chromium deficiency in human and animal nutrition, J. Trace. Elem. Exp. Med., 11: 241–250, 1998. [Google Scholar]
- 6. Shinde U.A., Goyal R.K., Insulin sensitizing action of chromium in experimental models of diabetes mellitus, Indian J. Pharmacol., 33: 51, 2001. [Google Scholar]
- 7. Shinde U.A., Goyal R.K., Mechanism of anti‐diabetic action of chromium, Indian J. Pharmacol., 34: 142, 2002. [Google Scholar]
- 8. Jensen P.K., Christiansen J.S., Steven K., Parving H.H., Renal function in streptozotocin‐diabetic rats, Diabetologia, 21: 409–414, 1981. [PubMed] [Google Scholar]
- 9. Bleasel A.F., Yong C.J., Streptozotocin induced diabetic nephropathy and renal tumors in the rat, Experientia, 38: 129–130, 1982. [DOI] [PubMed] [Google Scholar]
- 10. Domingo J.L., Gomez M., Llobet J.M., Corbella J., Keen C.L., Oral vanadium administration to streptozotocin‐diabetic rats has marked negative side‐effects which are independent of the form of vanadium used, Toxicology, 66: 279–287, 1991. [DOI] [PubMed] [Google Scholar]
- 11. Domingo J.L., Gomez M., Llobet J.M., Corbella J., Keen C.L., Improvement of glucose homeostasis by oral vanadyl or vanadate treatment in diabetic rats is accompanied by negative side effects, Pharmacol. Toxicol., 68: 249–253, 1991. [DOI] [PubMed] [Google Scholar]
- 12. Matsuda M., DeFronzo R.A., Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp, Diabetes Care, 22: 1462–1470, 1999. [DOI] [PubMed] [Google Scholar]
- 13. Ross M.H., Reith E.J., Romrell L.J., Histology. A text an atlas (ki sp k), Williams & Wilkins, Baltimore , Maryland , 1989, pp. 1–2. [Google Scholar]
- 14. Tisher C.C., Anatomy of the kidney In: Brenner B., Rector F., eds., The Kidney, vol.2, WB Saunders, Philadelphia , 1981, pp. 3–75. [Google Scholar]
- 15. Cam M.C., Pederson R.A., Brownsey R.W., McNeill J.H., Long‐term effectiveness of oral vanadyl sulfate in STZ‐diabetic rats, Diabetologia, 36: 218–224, 1993. [DOI] [PubMed] [Google Scholar]
- 16. Dai S., Yuen V.G., Orvig C., McNeill J.H., Prevention of diabetes‐induced pathology in STZ‐diabetic rats by bis(maltolato)oxovanadium (IV), Pharmacol. Commun., 3: 311–321, 1993. [Google Scholar]
- 17. Brown D.M., Andres G.A., Hostetter T.H., Mauer S.M., Price R., Venkatachalam M.A., Kidney complications, Diabetes, 31: 71–81, 1982. [DOI] [PubMed] [Google Scholar]
- 18. Cohen A.J., McGill P.D., Rossetti R.G., Guberski D.L., Like A.A., Glomerulopathy in spontaneously diabetic rats. Impact of glycemic control, Diabetes, 36: 944–951, 1987. [DOI] [PubMed] [Google Scholar]
- 19. Lee C.S., Mauer S.M., Brown D.M., Sutherland D.E., Michael A.F., Najarian J.S., Renal transplantation in diabetes mellitus in rats, J. Exp. Med., 139: 793–801, 1974. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20. Mauer S.M., Sutherland D.E.R., Steffes M.W., Leonard R.J., Najarian J.S., Michael A.F., Brown D.M., Pancreatic islet transplantation. Effects on the glomerular lesions of experimental diabetes in the rat, Diabetes, 23: 748–753, 1974. [DOI] [PubMed] [Google Scholar]
- 21. Fox C.J., Darby S.C., Ireland J.T., Sonkensen P.H., Blood glucose control and glomerular capillary basement membrane thickening in experimental diabetes, Br. Med. J., 2: 605–607, 1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Rasch P., Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment, Diabetologia, 16: 319–324, 1979. [DOI] [PubMed] [Google Scholar]
- 23. Rasch R., Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. The mesangial regions, Diabetologia, 17: 243–248, 1979. [DOI] [PubMed] [Google Scholar]
- 24. Rasch R., Prevention of diabetic glomerulopathy in streptozotocin diabetic rats by insulin treatment. Albumin excretion, Diabetologia, 18: 413–416, 1980. [DOI] [PubMed] [Google Scholar]
- 25. Evan A.P., Mong S.A., The effect of streptozotocin induced diabetes on kidney, Renal Physiol., 7: 78–89, 1984. [DOI] [PubMed] [Google Scholar]
- 26. Mertz W., Biological role of chromium, Fed. Proc., 26: 186–193, 1967. [PubMed] [Google Scholar]
- 27. Cerulli J., Grabe D.W., Gauthier I., Malone M., McGoldrick M.D., Chromium picolinate toxicity, Ann. Pharmacother., 32: 428–431, 1998. [DOI] [PubMed] [Google Scholar]
- 28. Wasser W.G., Feldman N.S., D'Agati V.D., Chronic renal failure after ingestion of over‐the‐counter chromium picolinate, Ann. Intern. Med. 126: 410, 1997. [DOI] [PubMed] [Google Scholar]
- 29. Glick M.E., Hoefs J.C., Meshkinpour H., Glucose intolerance and hepatic, biliary tract and pancreatic dysfunction, Dig. Dis. 5: 78–96, 1987. [DOI] [PubMed] [Google Scholar]